General Information


Targeted Genotypes: 1 – 6 or mixed genotype infections

Treatment Description: Epclusa (sofosbuvir/velpatasvir) is a nucleotide NS5B polymerase inhibitor. Nucleotide NS5B polymerase inhibitors directly target the hep C virus to stop it from making copies of itself in the liver.

Usage Warning: Patients with Bradycardia taking amiodarone can not take Sovaldi (sofosbuvir) in any combination.

Daily Dose: 1 pill

Length of Treatment:

For the treatment of chronic hepatitis C genotype 1 – 6 in patients:# of Weeks
Treatment-naïve and treatment-experienced with no cirrhosis or with cirrhosis.12
Treatment-naïve and treatment-experienced with decompensated cirrhosis.12 with RBV

Common Side Effects:

  • Anemia
  • Diarrhea
  • Difficulty sleeping
  • Headache
  • Nausea
  • Tiredness

BC’s PharmaCare Eligibility for Epclusa

Epclusa is a limited coverage drug. To qualify for treatment coverage a patients must have hep C genotype 1-6 or mixed genotype and all of the following :

  • Treatment prescribed by a hepatologist, a gastroenterologist, an infectious disease specialist or other physicians experienced with treating hepatitis C
  • Lab-confirmed hepatitis C
  • Not currently taking another hep C treatment
  • Detectable levels of hep C in the last 12 months
  • A liver fibrosis stage F0 or greater

Talk to your healthcare provider for more information or to start the treatment process.

Gilead’s Momentum Patient Assistance Program

Canadians prescribed Epclusa (sofosbuvir/velpatasvir) can request to be enrolled in the Gilead Momentum Program. For more information, contact your doctor, nurse, or call the Gilead Momentum Program at: 1-866-207-4267.